Moteur de recherche d’entreprises européennes
Financement de l’UE (10,4 M €) : Consortium international pour la prédiction de la génomique intégrative Hor17/12/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Consortium international pour la prédiction de la génomique intégrative
The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. Resulting in unprecedented potential for prediction, diagnosis, and personalised treatments for complex and rare diseases. Some of the largest biobanks in Europe and one in the USA will be securely linked and harmonized in a GDPR-compliant repository with data from more than 1.7 million genomes. INTERVENE will demonstrate the potential and benefits of powerful AI technologies on the next generation of integrative genetic scores (IGS). The clinical and economic benefits of IGS will be evaluated in key disease areas with major public health burden. Here, the newly developed IGS will be taken into clinical environment and their real-world benefits will be evaluated together with clinical experts, European patients advocate groups and medical societies and considering regulatory and ethical implications. Thus, a framework for legally and ethically responsible translation into wider clinical practice will be developed. Moreover, the partners will develop and test the role of IGS in several rare diseases as well as COVID-19 infection and severity. Importantly, to support the application of IGS via public-private partnerships including clinical practitioners, an AI-enabled federated data analysis platform, the ‘IGS4EU’ platform, will be developed for automated IGS generation and interpretation for end-users. Additionally, the IGS4EU platform will allow access of the INTERVENE data and the methodology know-how to the AI community through a competition-based benchmarking environment. In the long term, the IGS4EU platform aims to grow the disease coverage and enable a wide adoption of IGS as a gold standard in clinical research and practice.
| Aalto Korkeakoulusaatio sr | 537 626 € |
| Biobanks AND Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric) | 349 975 € |
| Cancer Patients Europe | 101 016 € |
| CSC-Tieteen Tietotekniikan Keskus Oy | 764 250 € |
| European Cancer Patient Coalition | 88 280 € |
| European Molecular Biology Laboratory | 1 682 319 € |
| Hasso-Plattner-Institut FUR Digital Engineering gGmbH | 753 201 € |
| Helsingin Yliopisto | 2 296 011 € |
| HUS-Yhtyma | 309 618 € |
| IBM Research GmbH | 0,00 € |
| Norges Teknisk-Naturvitenskapelige Universitet Ntnu | 258 000 € |
| PNO Life Sciences & Health B.V. | 231 344 € |
| Queen Mary University of London | 249 994 € |
| Tartu Ulikool | 1 148 849 € |
| Technische Universitaet Muenchen | 354 375 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 216 161 € |
| THE General Hospital Corporation | 247 343 € |
| Universita Degli Studi Di Siena | 552 044 € |
| Universita Degli Studi Di Torino | 294 535 € |
https://cordis.europa.eu/project/id/101016775
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.